IN8bio (INAB) H.C. Wainwright 28th Annual Global Investment Conference summary

Strategic overview and pipeline updates

• Focus on gamma delta T cell therapies and engagers for cancer and autoimmune diseases, leveraging unique cell properties for precision and safety.

• INB-600 platform advancing with INB-619, a CD19-targeting engager, entering IND-enabling studies; initial in vivo preclinical data expected in the second half of the year.

• Clinical program DeltEx DRI for glioblastoma shows median progression-free survival of 16 months for repeat dose patients, significantly above standard benchmarks.

• INB-100, an allogeneic product for high-risk leukemias, is progressing with a clinical update anticipated in late 2026.

• Company is actively seeking FDA guidance for regulatory pathways and planning for registrational trials.

Clinical data and safety profile

• Updated data from multiple centers show median progression-free survival of 13 months and median overall survival of 19.5 months for glioblastoma patients.

• Repeat dose patients nearly doubled progression-free survival compared to untreated controls.

• No major dose-limiting toxicities, cytokine release syndrome, or neurotoxicity observed, even with intracranial delivery.

• Gamma delta T cells' innate antibacterial and antiviral properties may reduce infection risk, with no catheter infections reported.

• Manufacturing and logistics costs remain manageable, with annual burn around $20 million.

T cell engager platform and differentiation

• INB-619 is a trispecific engager targeting CD19 and both delta 1 and delta 2 gamma delta T cell receptors, aiming for broad tissue targeting.

• Platform avoids CD3 targeting, reducing risk of T cell exhaustion and cytokine release syndrome, enabling higher dosing.

• Ex vivo data show complete B cell elimination in lupus donors, with animal model data expected this fall.

• Expansion domain in the engager drives gamma delta T cell proliferation, addressing limitations of previous approaches.

• Gamma delta T cells' innate immunity may help prevent infections commonly seen with other T cell engagers.